Symbiotec Pharmalab IPO open date is August 24, 2026 and the IPO will close on August 27, 2026. Symbiotec Pharmalab IPO is a Book built Issue. The company to raise around ₹1757 crores via IPO that comprises fresh issue of ₹150 crores and offer for sale up to 1,62,65,181 equity shares with face value of ₹2 each.
Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Symbiotec Pharmalab IPO to list on BSE, NSE on September 1, 2026. The allotment of Symbiotec Pharmalab IPO date is August 28, 2026.
The company reported revenue of ₹872.26 crores in 2026 against ₹755.98 crores in 2025. The company reported profit of ₹109.90 crores in 2026 against profit of ₹96.79 crores in 2025. As per the financials, the IPO investors should apply the IPO GMP for a long term.
Symbiotec Pharmalab Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 15 | 14820 | 414237 |
| sHNI | 14 | 210 | 207480 | 4277 |
| bHNI | 68 | 1020 | 1007760 | 8454 |
Symbiotec Pharmalab Reservation
| Category | Shares Offered | % |
|---|---|---|
| Total | 17786442 | 100% |
| QIB | 8876517 | 49.91% |
| HNI | 2662955 | 14.97% |
| Retail | 6213562 | 34.93% |
| Employee | 33408 | 0.19% |
Symbiotec Pharmalab About
IPO Details
| Total Issue Size | 17786442 shares (aggregating up to ₹1757 Cr) |
| Fresh Issue | 1521261 shares (aggregating up to ₹150.3 Cr) |
| Offer For Sale | 16265181 shares (aggregating up to ₹1607 Cr) |
| Face Value | ₹2/- Per Share |
| Issue Type | Book building IPO |
| Listing At | BSE NSE |
| Share Holding Pre Issue | 61,681,496 Equity Shares |
| Share Holding Post Issue | * |
Key Performance Indicators (KPI)
| KPI | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| RONW | 9.48% | 11.79% | 13.90% |
| EPS (BASIC) | 19.00 | 17.36 | 18.00 |
| P/E Pre IPO | 55.44 | ||
| P/E Post IPO | 56.81 |
Company Financial (In ₹Crore)
| Period Ended | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.9 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
Symbiotec Pharmalab IPO Dates
The Symbiotec Pharmalab IPO date is August 24 and the close date is August 27. The Symbiotec Pharmalab IPO allotment will be finalized on August 28 and the IPO listing on September 1.
| IPO Open Date: | August 24, 2026 |
| IPO Close Date: | August 27, 2026 |
| Basis of Allotment: | August 28, 2026 |
| Refunds: | August 31, 2026 |
| Credit to Demat Account: | August 31, 2026 |
| IPO Listing Date: | September 1, 2026 |
Peer Comparision (Valuation)
| Company | P/E (x) | CMP*(₹) | Face value (₹) |
|---|---|---|---|
| Symbiotec Pharmalab Limited | 55.44 | 988.00 | 2 |
| Concord Biotech Limited | 61.07 | 1,513.40 | 1 |
| Divi's Laboratories Limited | 87.8 | 8,495.00 | 2 |
| Cohance Lifesciences Limited | 95.02 | 444.70 | 1 |
| Laurus Labs Limited | 109.36 | 1,799.00 | 2 |
Promoters and Holding Pattern
The promoters of the company are Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
| Particular | Pre IPO Shares | Pre IPO % Shares | Post IPO Shares | Post IPO % Shares |
| Promoter and Promoter Group | 21,633,968 | 34.47% | – | -% |
| Others* | 40,047,528 | 65.53% | – | -% |
| Total | 6,16,81,496 | 100% | 6,32,02,757 | 100% |
Peer Comparision (Financial Performance)
| Company | NAV/Share (₹) | RoNW (%) | EPS (Basic) (₹) |
|---|---|---|---|
| Symbiotec Pharmalab Limited | 184.69 | 9.48% | 19.1 |
| Concord Biotech Limited | - | 14.00% | 24.78 |
| Divi's Laboratories Limited | 631 | 16.50% | 96.75 |
| Cohance Lifesciences Limited | - | 7.00% | 4.69 |
| Laurus Labs Limited | - | 16.80% | 16.47 |
About Company
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company caters to domestic and international markets across regulated and emerging regions.
The company focuses on research-driven manufacturing, quality compliance, and sustainable processes, serving the pharmaceutical, nutraceutical, and wellness industries. Its operations are supported by a focus on delivering ingredients aligned with global quality standards.
With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has received approvals from the US FDA, EU-GMP, Ministry of Food and Drug Safety, Korea, and other global organizations.
Strength
Global leadership in corticosteroid and steroidal-hormone APIs: The company has established expertise and a leadership position in the manufacturing of corticosteroid and steroidal-hormone APIs. Its specialized capabilities support its presence in the global pharmaceutical ingredients market.
Long-standing customer relationships: Symbiotec Pharmalab has developed long-standing relationships with domestic and international customers. These relationships support its established market presence and recurring business opportunities.
Vertically integrated manufacturing platform: The company operates a fully invested, multi-scale and vertically integrated manufacturing platform. Its integrated operations are supported by sustainable practices and a clean regulatory track record.
Risk Factors
Regulatory and quality compliance risk: The company's manufacturing facilities are subject to periodic inspections and audits by regulatory authorities and customers. Any manufacturing or quality control failure could result in regulatory action, reputational damage, and adverse effects on business and financial performance.
Dependence on export markets: The company generates a significant portion of its revenue from customers outside India, which contributed 66.67%, 55.19%, 59.97%, and 52.76% of revenue from operations in the three months ended June 30, 2025 and Fiscals 2025, 2024, and 2023, respectively. Inability to effectively manage risks associated with international sales could adversely affect overseas revenue and financial performance.
Dependence on Imported Raw Materials: The company procures a portion of its raw material requirements from countries including China and the United States. Any adverse developments in these countries or changes in the laws governing imports could disrupt the supply of raw materials and adversely affect the company's results of operations, financial condition, and cash flows.
IPO Lead Managers aka Merchant Bankers
- JM Financial Ltd.
- Avendus Capital Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
Company Address
Symbiotec Pharmalab Ltd.
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Symbiotec Pharmalab IPO FAQs
What is Symbiotec Pharmalab IPO?
Symbiotec Pharmalab IPO is Mainboard IPO. The company is going to raise ₹1,757 Crores via IPO. The issue is priced at ₹938 to ₹988 per equity share. The IPO is to be listed on BSE & NSE.
When Symbiotec Pharmalab IPO will open for subscription?
The IPO is to open on August 24, 2026 for QIB, NII, and Retail Investors. The IPO will close on August 27, 2026.
What is Symbiotec Pharmalab IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
How to Apply the Symbiotec Pharmalab IPO?
You can apply for Symbiotec Pharmalab IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
What is Symbiotec Pharmalab IPO Issue Size?
Symbiotec Pharmalab IPO issue size is ₹1757 crores.
What is Symbiotec Pharmalab IPO Price Band?
Symbiotec Pharmalab IPO Price Band is ₹938 to ₹988.
What is Symbiotec Pharmalab IPO Lot Size?
The minimum bid is 15 Shares with ₹14,820 amount.
What is the Symbiotec Pharmalab IPO Allotment Date?
Symbiotec Pharmalab IPO allotment date is August 28, 2026.
What is the Symbiotec Pharmalab IPO Listing Date?
Symbiotec Pharmalab IPO listing date is September 1, 2026. The IPO is to list on BSE & NSE.